Follow-On Biologics White Paper From FDA Could Be Delayed Until Fall
This article was originally published in The Pink Sheet Daily
Executive Summary
Policy implementation is likely to require agency action before legislative initiatives, according to Reed Smith attorney Deborah Shelton.
You may also be interested in...
FDA Drops Plans For Follow-On Biologics Policy
The agency does not plan to release documents or announce policies concerning follow-on proteins "in the near future," Deputy Commissioner Gottlieb says.
FDA Drops Plans For Follow-On Biologics Policy
The agency does not plan to release documents or announce policies concerning follow-on proteins "in the near future," Deputy Commissioner Gottlieb says.
Crawford Resigns; NCI Director Von Eschenbach Named To Top FDA Spot
Von Eschenbach appointed to be acting FDA commissioner following the Sept. 23 resignation of Lester Crawford.